In the past week, AGE stock has gone down by -34.50%, with a monthly decline of -40.42% and a quarterly plunge of -49.55%. The volatility ratio for the week is 7.63%, and the volatility levels for the last 30 days are 8.30% for AgeX Therapeutics Inc The simple moving average for the last 20 days is -36.74% for AGE stock, with a simple moving average of -41.70% for the last 200 days.
Is It Worth Investing in AgeX Therapeutics Inc (AMEX: AGE) Right Now?
Moreover, the 36-month beta value for AGE is 1.66. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
The public float for AGE is 21.46M and currently, short sellers hold a 0.43% of that float. On November 17, 2023, AGE’s average trading volume was 17.40K shares.
AGE) stock’s latest price update
AgeX Therapeutics Inc (AMEX: AGE) has seen a decline in its stock price by -33.77 in relation to its previous close of 0.59. However, the company has experienced a -34.50% decline in its stock price over the last five trading sessions. Proactive Investors reported 2023-08-30 that Privately-owned Serina Therapeutics Inc is being merged into AgeX Therapeutics (NYSE:AGE) in a move that will reboot the Nasdaq ‘human longevity’ stock, into an immunology and gene therapy firm seeking a treatment of Parkinson’s disease. Holders of Serina, a specialist in ‘small molecule’ central nervous system drug discovery, will own 75% of the combined company’s equity as a result of the ‘reverse merger’ transaction.
AGE Trading at -42.94% from the 50-Day Moving Average
After a stumble in the market that brought AGE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.16% of loss for the given period.
Volatility was left at 8.30%, however, over the last 30 days, the volatility rate increased by 7.63%, as shares sank -42.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -49.85% lower at present.
During the last 5 trading sessions, AGE fell by -36.58%, which changed the moving average for the period of 200-days by -50.51% in comparison to the 20-day moving average, which settled at $0.6003. In addition, AgeX Therapeutics Inc saw -29.62% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for AGE
When we switch over and look at the enterprise to sales, we see a ratio of 414.54, with the company’s debt to enterprise value settled at 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.24.
Conclusion
To wrap up, the performance of AgeX Therapeutics Inc (AGE) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
